FR3008317B1 - USE OF MICROORGANISMS TO DECREASE THE TRIMETHYLAMINE RATE IN A HUMAN BODY CAVITY, IN PARTICULAR FOR THE TREATMENT OF TRIMETHYLAMINURIA OR BACTERIAL VAGINOSIS AND THE PREVENTION OF CARDIOVASCULAR DISEASES - Google Patents

USE OF MICROORGANISMS TO DECREASE THE TRIMETHYLAMINE RATE IN A HUMAN BODY CAVITY, IN PARTICULAR FOR THE TREATMENT OF TRIMETHYLAMINURIA OR BACTERIAL VAGINOSIS AND THE PREVENTION OF CARDIOVASCULAR DISEASES

Info

Publication number
FR3008317B1
FR3008317B1 FR1356937A FR1356937A FR3008317B1 FR 3008317 B1 FR3008317 B1 FR 3008317B1 FR 1356937 A FR1356937 A FR 1356937A FR 1356937 A FR1356937 A FR 1356937A FR 3008317 B1 FR3008317 B1 FR 3008317B1
Authority
FR
France
Prior art keywords
trimethylaminuria
trimethylamine
microorganisms
prevention
decrease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR1356937A
Other languages
French (fr)
Other versions
FR3008317A1 (en
Inventor
Jean-Francois Brugere
Guillaume Borrel
Paul William O'toole
Corinne Malpuech-Brugere
Monique Alric
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universite Clermont Auvergne
Original Assignee
Universite Clermont Auvergne
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universite Clermont Auvergne filed Critical Universite Clermont Auvergne
Priority to FR1356937A priority Critical patent/FR3008317B1/en
Priority to PCT/EP2013/070249 priority patent/WO2014082773A1/en
Priority to CN201380069004.9A priority patent/CN104918633A/en
Priority to CA2893265A priority patent/CA2893265A1/en
Priority to EP13766995.8A priority patent/EP2925346A1/en
Priority to US14/648,186 priority patent/US10238695B2/en
Publication of FR3008317A1 publication Critical patent/FR3008317A1/en
Application granted granted Critical
Publication of FR3008317B1 publication Critical patent/FR3008317B1/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1003—Transferases (2.) transferring one-carbon groups (2.1)
    • C12N9/1007—Methyltransferases (general) (2.1.1.)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Mycology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
FR1356937A 2012-11-30 2013-07-15 USE OF MICROORGANISMS TO DECREASE THE TRIMETHYLAMINE RATE IN A HUMAN BODY CAVITY, IN PARTICULAR FOR THE TREATMENT OF TRIMETHYLAMINURIA OR BACTERIAL VAGINOSIS AND THE PREVENTION OF CARDIOVASCULAR DISEASES Expired - Fee Related FR3008317B1 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
FR1356937A FR3008317B1 (en) 2013-07-15 2013-07-15 USE OF MICROORGANISMS TO DECREASE THE TRIMETHYLAMINE RATE IN A HUMAN BODY CAVITY, IN PARTICULAR FOR THE TREATMENT OF TRIMETHYLAMINURIA OR BACTERIAL VAGINOSIS AND THE PREVENTION OF CARDIOVASCULAR DISEASES
PCT/EP2013/070249 WO2014082773A1 (en) 2012-11-30 2013-09-27 Use of microorganisms for reducing the level of trimethylamine in a human body cavity, in particular for the treatment of trimethylaminuria or of bacterial vaginosis and the prevention of cardiovascular diseases
CN201380069004.9A CN104918633A (en) 2012-11-30 2013-09-27 Use of microorganisms for reducing the level of trimethylamine in a human body cavity, in particular for the treatment of trimethylaminuria or of bacterial vaginosis and the prevention of cardiovascular diseases
CA2893265A CA2893265A1 (en) 2012-11-30 2013-09-27 Use of microorganisms for reducing the level of trimethylamine in a human body cavity in particular for the treatment of trimethylaminuria or of bacterial vaginosis and the prevention of cardiovascular diseases
EP13766995.8A EP2925346A1 (en) 2012-11-30 2013-09-27 Use of microorganisms for reducing the level of trimethylamine in a human body cavity, in particular for the treatment of trimethylaminuria or of bacterial vaginosis and the prevention of cardiovascular diseases
US14/648,186 US10238695B2 (en) 2012-11-30 2013-09-27 Use of microorganisms for reducing the level of trimethylamine in a human body cavity, in particular for the treatment of trimethylaminuria or of bacterial vaginosis and the prevention of cardiovascular diseases

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR1356937A FR3008317B1 (en) 2013-07-15 2013-07-15 USE OF MICROORGANISMS TO DECREASE THE TRIMETHYLAMINE RATE IN A HUMAN BODY CAVITY, IN PARTICULAR FOR THE TREATMENT OF TRIMETHYLAMINURIA OR BACTERIAL VAGINOSIS AND THE PREVENTION OF CARDIOVASCULAR DISEASES

Publications (2)

Publication Number Publication Date
FR3008317A1 FR3008317A1 (en) 2015-01-16
FR3008317B1 true FR3008317B1 (en) 2017-04-28

Family

ID=49911601

Family Applications (1)

Application Number Title Priority Date Filing Date
FR1356937A Expired - Fee Related FR3008317B1 (en) 2012-11-30 2013-07-15 USE OF MICROORGANISMS TO DECREASE THE TRIMETHYLAMINE RATE IN A HUMAN BODY CAVITY, IN PARTICULAR FOR THE TREATMENT OF TRIMETHYLAMINURIA OR BACTERIAL VAGINOSIS AND THE PREVENTION OF CARDIOVASCULAR DISEASES

Country Status (1)

Country Link
FR (1) FR3008317B1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017083549A1 (en) * 2015-11-10 2017-05-18 Probiotech Llc Probiotic delivery systems
US20190388344A1 (en) 2018-06-22 2019-12-26 Probiotech Llc Method to Improve The Health Of The Microbiome In A Human Gastrointestinal System and Multi-Chamber Probiotic Delivery Products Therefor

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4115340A1 (en) * 1991-05-10 1992-11-12 Forschungszentrum Juelich Gmbh MICROBIOLOGICALLY PREPARED TRIMETHYLAMINE DEHYDROGENASE, METHOD FOR THEIR OBTAINMENT AND ITS USE
WO2002061425A2 (en) * 2001-02-01 2002-08-08 Q-Scent Ltd. Diagnostic method and apparatus for detecting biogenic amines

Also Published As

Publication number Publication date
FR3008317A1 (en) 2015-01-16

Similar Documents

Publication Publication Date Title
EP2916827A4 (en) METHODS AND DEVICES FOR THE TREATMENT OF OCULAR DISEASES IN HUMAN SUBJECTS
IL260214A (en) Cell-based treatment and drug discovery in hirschsprung's disease enabled by pluripotent stem cell-derived human enteric neural crest lineages
EP2532680A4 (en) MEDICINAL COMPOSITION FOR THE TREATMENT AND / OR PREVENTION OF CANCER
EP2542060A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT AND / OR PREVENTION OF CARDIOVASCULAR DISEASES
EP2651407A4 (en) 3-METHANESULFONYLPROPIONITRILE FOR THE TREATMENT OF INFLAMMATION AND PAIN
WO2013169864A3 (en) TETRAHYDRO[1,8]NAPHTHYRIDINE SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORƴ AND THE TREATMENT OF DISEASE
EP3723513A4 (en) FERMENTATION PROBIOTICS AND METABOLITES FOR THE PREVENTION AND TREATMENT OF DISEASES IN ANIMALS
EP2672927A4 (en) EARLY APPENDIX OCCLUSION AND TREATMENT OF ARRHYTHMIA
EP2774616A4 (en) APPLICATION OF ROSEBURIA IN THE TREATMENT AND PREVENTION OF OBESITY-RELATED DISEASES
ZA201304638B (en) Composition for use in the prevention and /or treatment of skin condition and skin diseases.
EA201590204A1 (en) SOLID COMPOSITION, CONTAINING IRON, FOR APPLICATION IN IRON DEFICIENCY STATES
MX2015002289A (en) Human antibodies to gfrî±3 and methods of use thereof.
EP2903597A4 (en) USE OF MICROVESICLES IN THE DIAGNOSIS, PROGNOSIS AND TREATMENT OF DISEASES AND MEDICAL CONDITIONS
FR2994386B1 (en) INHIBITION OF ADHESION OF PATHOGENIC MICROORGANISMS BY SUCROSE AND / OR SORBITAN ESTER IN THE COSMETIC TREATMENT OF SKIN ATOPIA
EP2925312A4 (en) USE OF ENTACAPONE TO PREVENT AND TREAT OBESITY AND ASSOCIATED METABOLIC DISEASES
EP2739244A4 (en) SYSTEMS, METHODS AND IMPLANTS IN THE TREATMENT OF PROLAPSUS OR INCONTINENCE
IL251543A0 (en) Use of gel compounds in the production of medicine to prevent or treat skin diseases
PH12016501087B1 (en) Lactobacillus salivarius for the treatment of mastitis
FR2958163B1 (en) PREPARATION FROM IN VITRO CULTURE OF NON-ELICITED ARGANIER DIFFERENTIAL CELLS, USE THEREOF FOR THE TREATMENT OF SKIN AGING, INFLAMMATION AND HEALING, AND OBTAINING THEM.
EP2854910A4 (en) CERAMIDE LEVELS IN THE TREATMENT AND PREVENTION OF INFECTIONS
EP2823717A4 (en) USE OF HUMULUS JAPONICUS EXTRACT FOR THE PREVENTION OR TREATMENT OF METABOLIC DISORDERS OR HEPATIC STEATOSIS
FR2922450B1 (en) USE OF LACTIC ACID BACTERIA FOR THE PREVENTION AND / OR TREATMENT OF SKIN CONDITIONS
HK1206984A1 (en) Combination therapy of anti-mif antibodies and glucocorticoids
EP2548893A4 (en) DOUBLE ANTAGONIST FOR TNF- AND IL-21 IN THE PREVENTION AND TREATMENT OF AUTOIMMUNE DISEASES
FR3008317B1 (en) USE OF MICROORGANISMS TO DECREASE THE TRIMETHYLAMINE RATE IN A HUMAN BODY CAVITY, IN PARTICULAR FOR THE TREATMENT OF TRIMETHYLAMINURIA OR BACTERIAL VAGINOSIS AND THE PREVENTION OF CARDIOVASCULAR DISEASES

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 3

PLFP Fee payment

Year of fee payment: 4

PLFP Fee payment

Year of fee payment: 5

TP Transmission of property

Owner name: UNIVERSITE CLERMONT AUVERGNE, FR

Effective date: 20171113

PLFP Fee payment

Year of fee payment: 6

PLFP Fee payment

Year of fee payment: 8

PLFP Fee payment

Year of fee payment: 9

PLFP Fee payment

Year of fee payment: 10

ST Notification of lapse

Effective date: 20240305